1st February 2007
American Heart Association
American College of Cardiology
Society for Cardiovascular Angiography and Interventions
American College of Surgeons
American Dental Association
American College of Physicians
Summary, Abstract,

Source: National Guidelines Clearinghouse

GUIDELINE OBJECTIVE(S)

To emphasize the potential complications of premature discontinuation of thienopyridine therapy and to address potential strategies to minimize this occurrence

TARGET POPULATION

Patients who have received coronary artery stents within the past year

INTERVENTIONS AND PRACTICES CONSIDERED

1. Continuation of dual antiplatelet therapy (aspirin, thienopyridines) for 12 months after placement of drug-eluting stents
2. Education of patients and healthcare providers about hazards of premature discontinuation of antiplatelet therapy
3. Deference of elective procedures with significant risk of bleedings
4. Continuation of aspirin if thienopyridine therapy is discontinued

MAJOR OUTCOMES CONSIDERED

• Rates of stent thrombosis, myocardial infarction (MI), and death
• Ratio of death to nonfatal MI